

**Amendments to the Claims:**

1. **(Currently Amended)** A dry process for the preparation of stable valganciclovir hydrochloride solid dosage forms wherein the process comprises mixing amorphous valganciclovir hydrochloride with one or more pharmaceutically acceptable excipient(s) and forming into a solid dosage form, wherein the solid dosage form does not show conversion of amorphous valganciclovir hydrochloride to crystalline valganciclovir hydrochloride after storage for two months at 40° C and 75% relative humidity.
2. **(Original)** The process according to claim 1 wherein the pharmaceutically acceptable excipient is one or more of filler, binder, disintegrant, glidant and lubricant.
3. **(Currently Amended)** The process according to claim 1 wherein the process comprises compacting valganciclovir hydrochloride alone or mixed with one or more of pharmaceutically acceptable excipient(s) by roller compactor or slugging; sizing the compacts or slugs into granules by milling; optionally mixing the granules with one or more of pharmaceutically acceptable excipients and forming a solid dosage form.
4. **(Original)** The process according to claim 1 wherein the compaction is done by roller compactor.
5. **(Original)** The process according to claims 1 wherein the solid dosage form is a tablet.
6. **(Original)** The process according to claim 1 wherein the solid dosage form is a capsule.
7. **(Original)** The process according to claim 1 wherein the mixture is directly compressed into a tablet.
8. **(Original)** The process according to claim 2 wherein the filler is selected from the group consisting of microcrystalline cellulose, mannitol, sucrose, lactose, dextrose, calcium carbonate, and a mixture thereof.
9. **(Original)** The process according to claim 2 wherein the binder is selected from the group consisting of polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, starch and starch based binders, gelatin, gums and a mixture thereof.
10. **(Original)** The process according to claim 2 wherein the disintegrant is selected from the group consisting of crospovidone, croscarmellose sodium, starch, hydroxypropylcellulose, hydroxypropylmethylcellulose, gums, sodium starch glycolate and a mixture thereof.

11. **(Original)** The process according to claim 2 wherein the glidant is selected from the group consisting of talc, colloidal silicon dioxide and a mixture thereof.
12. **(Original)** The process according to claim 2 wherein the lubricant is selected from the group consisting of magnesium stearate, stearic acid, sodium stearyl fumarate and a mixture thereof.
13. **(Presently Canceled)**
14. **(Presently Canceled)**
15. **(Presently Canceled)**
16. **(Presently Canceled)**
17. **(Presently Canceled)**
18. **(Presently Canceled)**